Dr. Dummer on COMBI-AD Trial Results in BRAF-Mutant Melanoma

Video

Reinhard Dummer, MD, of University Hospital Zurich, discusses the results of the phase III COMBI-AD study presented at the 2017 ESMO Congress in patients with stage III BRAF-mutant melanoma.

Reinhard Dummer, MD, of University Hospital Zurich, discusses the results of the phase III COMBI-AD study presented at the 2017 ESMO Congress in patients with stage III BRAF-mutant melanoma.

This is a prospective randomized placebo-controlled trial of 900 enrolled patients who had previously undergone complete resection of all metastatic disease. They were then randomized to receive the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) or placebo. The treatment duration was 1 year and the primary endpoint was relapse-free survival (RFS).

There was a clear advantage for the combination over placebo, Dummer explains. The hazard ratio was below 0.5. Other endpoints, aside from RFS, were positive, including distant metastases-free survival and overall survival.

<<< View more from the 2017 ESMO Congress

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center